Podcasts

Drs Razavi and Ross note the evolution of ESR1 mutation–directed breast cancer management, including the role of genomic testing at metastatic recurrence.

Peter Enzinger, MD, answers common questions about the diagnosis and management of esophageal cancer in this clinician-focused FAQ interview.

Luhua (Michael) Wang, MD, discusses the implications of the FDA approval of brexu-cel for the treatment of adult patients with relapsed/refractory MCL.

Drs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.

Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.

Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.

Drs Armstrong and Tawagi provide a comprehensive review of metastatic urothelial carcinoma management.

Dr Cooper discusses recent advances that have reshaped the treatment paradigm for small cell lung cancer, particularly in the relapsed setting.

Drs Nunnery and Kang discuss the rapidly evolving treatment paradigm for first-line metastatic TNBC, including the emergence of novel ADCs.

Drs Camidge and Meguid discuss Dr Meguid’s journey into medicine, his surgical interests, and how personal experiences shape perspectives on patient care.

Drs Armstrong and Tawagi review localized bladder cancer diagnosis and management, including initial histology and evolving treatment paradigms.

Drs Matulonis and Stover explore the biology and therapeutic relevance of the RAS/MAP kinase pathway in gynecologic cancers.

Drs Nunnery and Iyengar highlight the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

Camidge and O'Donnell discussed O’Donnell’s career, which has culminated in his role as director of Research Partnerships at Cancer Research Society.